Key result
Carvedilol (HR 0.92; CI 0.78-1.09) and bisoprolol (HR 1.04; CI 0.93-1.16) showed no significant difference in all-cause mortality compared to metoprolol tartrate in older adults with heart failure.
Why the study?
Do carvedilol or bisoprolol reduce all-cause mortality compared to metoprolol tartrate in older adults following a primary hospital admission for heart failure?
Cohort (n=3,197)
Do carvedilol or bisoprolol reduce all-cause mortality compared to metoprolol tartrate in older adults following a primary hospital admission for heart failure?
Effect estimate: HR 0.92 and HR 1.04 (95% CI 0.78-1.09 and 0.93-1.16)
Among older adults hospitalized for heart failure, there was no significant difference in all-cause mortality between those treated with carvedilol, bisoprolol, or metoprolol tartrate.
No takes yet. Share an insight, caveat, or question.
No mortality difference seen among beta-blockers in older HF patients; should not yet change practice and leaves optimal selection open.
Perreault et al. (2016) conducted a cohort in Heart failure (n=3,197). Carvedilol or bisoprolol vs. Metoprolol tartrate was evaluated on All-cause mortality (HR 0.92 and HR 1.04, 95% CI 0.78-1.09 and 0.93-1.16). Carvedilol (HR 0.92; CI 0.78-1.09) and bisoprolol (HR 1.04; CI 0.93-1.16) showed no significant difference in all-cause mortality compared to metoprolol tartrate in older adults with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: